文献速递妇产影像技术与安全PETCTMR

正电子发射断层显像用于局部晚期宫颈癌分期及评估调强放疗方案

Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach.
PubMed 文献 · Radiol Med · 2019-03-23

本研究前瞻性纳入14例局部晚期宫颈癌患者,采用18FDG-PET/CT指导的调强放疗同步整合推量联合顺铂化疗。中位随访30个月,2年局部控制率和远处控制率均为86%,无4级急性和/或晚期毒性。18FDG-PET/CT因对远处转移和淋巴结受累检测的高特异度而影响了分期评估和放疗计划。

要点

  • 18FDG-PET/CT对远处转移和淋巴结受累检测具有高特异度,可影响局部晚期宫颈癌的分期评估和放疗计划。
  • 基于18FDG-PET/CT的同步整合推量对阳性淋巴结进行加量,中位剂量54 Gy/27次。
  • 中位随访30个月,2年局部控制率和远处控制率均为86%,无4级急性和/或晚期毒性。

核心结论

  • 18FDG-PET/CT因对远处转移和淋巴结受累检测的高特异度而影响了分期评估和放疗治疗计划;对阳性淋巴结采用调强放疗同步整合推量是局部晚期宫颈癌的有效治疗,毒性可接受。

研究设计与样本

  • 前瞻性研究,2014年8月至2017年6月期间招募14例宫颈癌患者,其中13例(93%)为局部晚期宫颈癌,1例(7%)因18FDG-PET/CT发现先前CT/MRI未检测到的肝转移而不可评估。患者接受同步化疗和调强放疗,同步整合推量基于18FDG-PET/CT计划对阳性淋巴结实施,随后行CT计划的高剂量率近距离放疗作为原发肿瘤的后续推量,调强放疗期间给予顺铂同步化疗。

诊断标准与关键数值

  • 同步整合推量对23枚阳性淋巴结实施;调强放疗骨盆中位剂量48.6 Gy/27次,同步整合推量中位剂量54 Gy/27次,高剂量率近距离放疗推量中位剂量21 Gy/3次。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIMS: To evaluate toxicity and outcome of concomitant chemotherapy and intensity modulated radiotherapy (IMRT) with 18-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) based simultaneous integrated boost (SIB) of locally advanced cervical cancer (LACC).

METHODS: Patients with LACC underwent chemo-radiation with IMRT and SIB. Staging and follow-up were performed with clinical evaluation and CT, MRI, 18FDG-PET/CT. SIB was done on positive nodes with 18FDG-PET/CT based planning. CT-based planning high-dose-rate brachytherapy (HDR-BT) was delivered as subsequent boost to the primary tumor. Cisplatin concomitant chemotherapy was administered during IMRT.

RESULTS: Fourteen patients with cervical cancer were prospectively recruited between August 2014 and June 2017, 13 (93%) had a LACC, one (7%) patient was not evaluable because 18FDG-PET/CT evidenced metastases to the liver undetected by previous CT/MRI. Patients had a median age of 59 years, a median Karnofsky performance status of 100%, and a prevalence of squamous cell carcinoma histology (85%). SIB was delivered on 23 positive lymph nodes. IMRT median dose to the pelvis was 48.6 Gy in 27 fractions, SIB median dose 54 Gy in 27 fractions, HDR-BT boost median dose 21 Gy in 3 fractions. After a median follow-up of 30 months, 2-year local control and distant control were 86% and 86%, respectively. There were no grade 4 acute and/or late toxicities.

CONCLUSIONS: The 18FDG-PET/CT influenced stage assessment and RT treatment planning due to its high specificity in distant metastases and nodal involvement detection. The IMRT with SIB for positive nodes was an effective therapy with acceptable toxicity in LACC.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Draghini L, Costantini S, Vicenzi L, et al. Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach. Radiol Med. 2019. PMID: 30904982. doi:10.1007/s11547-019-01023-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。